Two molecules in blood cells may be potential biomarkers for diagnosing myasthenia gravis (MG), a study suggests. Researchers found…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
A man developed myasthenia gravis (MG), which quickly progressed to an advanced stage, shortly after surgery to remove a tumor…
A woman was diagnosed with both ocular myasthenia gravis (MG) and a hereditary form of motor neuropathy, a condition…
Long-term treatment with Vyvgart (efgartigimod alfa-fcab) is safe and well tolerated, and leads to a sustained improvement in…
More or larger clusters of developing B-cells, called germinal centers, in the thymus may predict better outcomes after thymus removal…
This year’s MGNet Scholar award, funded by the Myasthenia Gravis Rare Disease Network (MGNet), has gone to a scientist…
Nearly half of all people with myasthenia gravis (MG) in Poland were admitted…
Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them…
Diabetes, which causes blood sugar levels to rise abnormally, may trigger a stronger immune response and worsen myasthenia gravis…
Soliris (eculizumab) appears to be safe and effective for patients with hard-to-treat generalized myasthenia gravis (gMG) who have acetylcholine receptor…